AIMM Therapeutics Overview

  • Founded
  • 2004
  • Status
  • Private
  • Employees
  • 9
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $25M
Latest Deal Amount
  • Investors
  • 6

AIMM Therapeutics General Information


Developer of therapeutic human monoclonal antibodies designed to offer treatment of cancer and infectious diseases. The company's human monoclonal antibodies and antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of promising antibodies from humans or animals, thus enabling healthcare organizations to provide patients with quality care in a cost-efficient manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • Meibergdreef 59
  • 1105 BA Amsterdam
  • Netherlands
+31 020 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AIMM Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 01-Jan-2018 $25M 000.00 Completed Generating Revenue
3. Corporate 07-Jun-2013 00.000 00.000 000.00 Completed Generating Revenue
2. Seed Round 01-Jun-2009 $1.37M $1.37M Completed Startup
1. Joint Venture 01-Jan-2004 Completed Startup
To view AIMM Therapeutics’s complete valuation and funding history, request access »

AIMM Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
John Womelsdorf Ph.D Chief Executive Officer
Eric van der Aa Ph.D Chief Operating Officer
You’re viewing 2 of 6 executive team members. Get the full list »

AIMM Therapeutics Board Members (6)

Name Representing Role Since
Douglas Manion MD AIMM Therapeutics Board Member 000 0000
Timothy Wright MD Self Board Member 000 0000
You’re viewing 2 of 6 board members. Get the full list »

AIMM Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AIMM Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cosmo Pharmaceuticals Corporation Minority 000 0000 000000 0
Cancer Research UK Venture Capital Minority 000 0000 000000 0
Life Sciences Fund Amsterdam Venture Capital Minority 000 0000 000000 0
UvA Ventures Holding Accelerator/Incubator Minority 000 0000 000000 0
Immpact Corporation Majority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »